Novel NeuroAIDS Therapeutics: Integrated Preclinical/Clinical Program (P01)
Post Date
July 8th 2013
Application Due Date
January 7th 2016
Funding Opportunity Number
PAR-13-267
CFDA Number(s)
93.242
Funding Instrument Type(s)
Grant
Funding Activity Categories
Eligibility Categories
State Governments
County Governments
City or Township Governments
Special District Governments
Independent School Districts
Public and State Controlled Institutions of Higher Education
Federally Recognized Native American Tribal Governments
Public Housing Authorities or Indian Housing Authorities
Non-Federally Recognized Native American Tribal Organizations
Non-Profits With 501 (c) (3) Status With The IRS (Except Higher Education Institutions)
Non-Profits Without 501 (c) (3) Status With The IRS (Except Higher Education Institutions)
Private Institutions of Higher Education
For-Profit Organizations (Except Small Businesses)
Small Businesses
Other
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Funding
-
Award Range:
$None - $None
Grant Description
The National Institute of Mental Health invites research grant applications to develop innovative programs to advance therapeutics for NeuroAIDS. This Funding Opportunity Announcement (FOA) will support research programs that will advance central nervous system (CNS)-focused therapeutic approaches to: a) address HIV-associated neurocognitive disorders in HIV-infected individuals on highly active anti-retroviral therapy (HAART), b) eradicate persistent HIV-1 from the CNS during chronic infection, c) prevent establishment of HIV-1 in the brain during early infection, and d) assess the potential for CNS toxicity using HAART or candidate drugs that are currently in clinical studies to eradicate HIV-1. Studies to create or adapt existing animal models of HIV-1 infection in the CNS may be proposed to enable assessment of novel HIV CNS-focused therapeutic candidates. Multi-disciplinary, multi-project programs that are focused on improving neurocognition in HIV-infected persons are encouraged. A well defined, synergistic and milestone-driven plan for discovery, preclinical, and/or early clinical hypothesis-driven research should be presented. Public-private partnerships are encouraged but not required.
Contact Information
-
Agency
Department of Health and Human Services
-
Office:
National Institutes of Health
-
Agency Contact:
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV -
Agency Mailing Address:
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
- Agency Email Address:
- More Information:
Get A Free Grant Assistance Kit
To start your application for a free grant package go to: